Top

Osteoporosis International

Published in:

01-08-2019 | Metastasis | Case Report

Diffuse osteosclerosis as a presentation of recurrent breast cancer: role of endothelin 1

Authors: K. G. Zarnecki, J. Kristianto, J. Charlson, B. Wilson, R. D. Blank, J. L. Shaker

Published in: Osteoporosis International | Issue 8/2019

Abstract

Summary

We report a 46-yr-old woman with a history of breast cancer who presented with diffuse myalgias, bone pain, and osteosclerosis. She was found to have recurrent breast cancer producing endothelin-1.

Introduction

Acquired osteosclerosis can be caused by various disorders. Endothelin -1 is believed to contribute to osteosclerosis caused by breast cancer.

Methods

Although the bone marrow biopsy did not reveal breast cancer, she developed skin lesions consistent with metastatic breast cancer. She ultimately died from progressive disease. At autopsy immunohistochemistry for endothelin-1 was performed on a section from the L5 vertebral body.

Results

The section from the L5 vertebral body showed small foci of cells consistent with metastatic carcinoma and a prominent sclerotic response. Immunohistochemistry for endothelin-1 was strongly positive.

Conclusions

Recurrent breast cancer may present with diffuse osteosclerosis. Endothelin-1 may be a paracrine factor responsible for increased bone formation and osteosclerosis.

Available only for authorised users

Rosol TJ (2000) Pathogenesis of bone metastases: role of tumor related proteins. J Bone Miner Res 15:844–850CrossRefPubMed

Eck L, Graves L III, Lukert B, Bhattacharya (2008) Sclerotic bone changes on densitometry testing in a patient with a remote history of breast cancer. Endocr Pract 14(1):125–126CrossRefPubMed

Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19(1):18–54. https://doi.org/10.1210/edrv.19.1.0323 CrossRefPubMed

Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA (1994) Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54(9):2372–2377PubMed

Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, con Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577–2581PubMed

Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096–4102PubMed

Nelson JB, Chan-Tach K, Hedican SP, Magnuson SR, Opgenorth TJ, , Bova GS, & Simons JW. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate Cancer (1996) Cancer Res 56, 663–668PubMed

Nelson JB, Hedican SP, Geroge DJ, Reddi AH, Piantadosi S, Eisenberger AA, Simons JW (1995) Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944–949CrossRefPubMed

Nelson JB, Nguyne SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW, Inoue N (1999) New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin a receptor blockade. Urology 53:1063–1069CrossRefPubMed

10.

Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ (2016 Apr) Endothelin. Pharmacol Rev 68(2):357–418. https://doi.org/10.1124/pr.115.011833 CrossRefPubMedPubMedCentral

11.

Rosanò L, Spinella F, Bagnato A (2013) Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 13(9):637–651. https://doi.org/10.1038/nrc3546 CrossRefPubMed

12.

Guise TA (2003) A causual role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. PNAS 100(19):10954–10959CrossRefPubMed

13.

Tamkus D, Sikorskii A, Gallo K, Wiese D, Leece C, Madhukar B, Chivu S, Chitneni S, Dimitrov N (2013) Endothelin-1 enriched tumor phenotype predicts breast cancer recurrence. ISRN Oncol 2013:7

14.

Kedzierski RM, Yanagisawa M (2001) Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41:851–876CrossRefPubMed

15.

Malek AM, Greene AL, Izumo S (1993) Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci U S A 90:5999–6003CrossRefPubMedPubMedCentral

16.

Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M (1994) ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78:473–485CrossRefPubMed

17.

Wolff K, Nisell H, Carlström K, Kublickiene K, Hemsén A, Lunell N-O, Lindblom B (1996) Endothelin-1 and big endothelin-1 levels in normal term pregnancy and in preeclampsia. Regul Pept 67(3):211–216. https://doi.org/10.1016/s0167-0115(96)00122-x CrossRefPubMed

18.

Ken-Dror S, Weintraub Z, Yechiely H, Kahana L (2008) Atrial natriuretic peptide and endothelin concentrations in human milk during postpartum lactation. Acta Paediatr 86(8):793–795. https://doi.org/10.1111/j.1651-2227.1997.tb08599.x CrossRef

19.

Clines G, Mohammad KS, Bao Y, Stephens O, Suva L, Shaughnessy JD, Fox JW, Chirgwin J, Guise T (2007) Dickkopf homolog 1 mediates Endothelin-1-stimulated new bone formation. Mol Endocrinol 21(2):486–498CrossRefPubMed

20.

Johnson MG, Kristianto J, Yuan B, Konicke K, Blank R (2014) Big endothelin changes the cellular miRNA environment in TMOb osteoblasts and increases mineralization. Connect Tissue Res 55(Suppl 1):113–116CrossRefPubMedPubMedCentral

21.

Qi P, Chen M, Zhang LX, Song RX, He ZH, Wang ZP (2015) A meta-analysis and indirect comparison of endothelin a receptor antagonist for castration-resistant prostate cancer. PLoS One 10(7):e0133803CrossRefPubMedPubMedCentral

Title: Diffuse osteosclerosis as a presentation of recurrent breast cancer: role of endothelin 1
Authors: K. G. Zarnecki
J. Kristianto
J. Charlson
B. Wilson
R. D. Blank
J. L. Shaker
Publication date: 01-08-2019
Publisher: Springer London
Keywords: Metastasis
Breast Cancer
Breast Cancer
Published in: Osteoporosis International / Issue 8/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-019-04998-5

At a glance: The STEP trials

Springer Medicine

Diffuse osteosclerosis as a presentation of recurrent breast cancer: role of endothelin 1

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2019

Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis

Vertebral bone attenuation in Hounsfield Units and prevalent vertebral fractures are associated with the short-term risk of vertebral fractures in current and ex-smokers with and without COPD: a 3-year chest CT follow-up study

Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. Wolf

Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis

High FGF23 levels are associated with impaired trabecular bone microarchitecture in patients with osteoporosis

Hypoglycaemia and type 1 diabetes are associated with an increased risk of fractures